I-Corps: Point-of-Care Micro Biochip for Cancer Diagnostics

I-Corps：用于癌症诊断的即时护理微型生物芯片

• 批准号: 1643861
• 负责人: Eon Soo Lee
• 金额: $ 5万
• 依托单位: New Jersey Institute of Technology
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-01 至 2017-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1643861&HistoricalAwards=false
• 关键词: Corps; Point; Care; Micro; Biochip

The broader impact/commercial potential of this I-Corps project are primarily focused on the societal need for early diagnosis of cancer and the market for commercial applications of disease detection and diagnosis. Cancer remains the second most common cause of death in the US, accounting for nearly 1 of every 4 deaths. The early detection of cancers can enhance preventive measures, increase curability of the disease, reduces health care costs and finally improves the quality of life for patients. The cancer diagnosis process can be a simple self-evaluation process using the point-of-care (POC) micro biochip technology. Therefore, anyone who needs to diagnose the existence and severity of cancer, can perform simple self-check by a POC biochip device. The biochip also has a huge potential in numerous applications in disease diagnosis, drug delivery, 'organ on a chip' and 'lab on a chip' biomedical devices with advantages over the most of the complicated diagnosis processes and sophisticated expensive equipment due to its simple, quick and inexpensive methodology.This I-Corps project is primarily intended to commercialize the point-of-care (POC) micro biochip technology which can diagnose cancer. To achieve the early detection of specific cancer type, the biochip is incorporated with a highly sensitive and specific set of cancer biomarkers and the sensing technology. To increase the sensing capability, the biochip is fabricated with microchannels that are designed to create blood flow without the any external source. The biological reaction is captured using the biochip sensing technology that is developed using highly sensitive nano-circuit design in the biochip. Also, the cancer severity is sensed depending on the intensity of the signal output. Therefore, the cancer and its severity can be diagnosed using the micro biochip.

这个I-Corps项目的更广泛的影响/商业潜力主要集中在癌症早期诊断的社会需求和疾病检测和诊断的商业应用市场。癌症仍然是美国第二大常见的死亡原因，占每4例死亡中的近1例。癌症的早期检测可以加强预防措施，提高疾病的可治愈性，降低医疗费用，最终提高患者的生活质量。癌症诊断过程可以是使用即时护理（POC）微型生物芯片技术的简单自我评估过程。因此，任何需要诊断癌症的存在和严重程度的人都可以通过POC生物芯片设备进行简单的自我检查。生物芯片在疾病诊断、药物输送、“芯片上的器官”和“芯片上的实验室”生物医学设备中的许多应用中也具有巨大的潜力，由于其简单，这个I-Corps项目的主要目的是将即时护理（POC）商业化，微型生物芯片技术可以诊断癌症。为了实现特定癌症类型的早期检测，生物芯片结合了一套高度敏感和特异性的癌症生物标志物和传感技术。为了增加传感能力，生物芯片制造有微通道，这些微通道被设计成在没有任何外部来源的情况下产生血液流动。使用生物芯片传感技术捕获生物反应，该技术是使用生物芯片中的高灵敏度纳米电路设计开发的。此外，根据信号输出的强度感测癌症严重程度。因此，可以使用微型生物芯片诊断癌症及其严重程度。

项目成果

Innovative Point-of- Care (POC) Micro Biochip for Early Stage Ovarian Cancer Diagnostics

用于早期卵巢癌诊断的创新护理点 (POC) 微型生物芯片

• DOI: 10.1002/9780470015902.a0026245
• 发表时间: 2017
• 期刊: Sensors & Transducers
• 作者: B. Nunna;D. Mandal;S. Zhuang;Eon Soo Lee
• 通讯作者: Eon Soo Lee